What is it about?
In patients with Homozygous Familial Hypercholesterolemia, therapy starts at so young an age that it is imperative to balance the short-term lipid target with the long-term negative effects of therapy. A ‘personalized’ therapeutic regimen, aimed at quoad valetudinem, allowed for social cost reduction, complete regression of lipid deposition and an acceptable patient quality of life.
Featured Image
Photo by ipet photo on Unsplash
Why is it important?
we described a personalized therapeutic regimen as a paradignatic case management in Homozygous Familial Hypercholesterolemia aimed at life saving and acceptable quality of life.
Perspectives
I hope that this article encourages other physicians to feal free to personalize therapies, in rare forms of inherited dyslipidemias, applyng guide lines if and when appropriated for the patient's long perspective.
Tiziana Sampietro
Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e di Sanita Pubblica
Read the Original
This page is a summary of: Null receptor homozygous familial hypercholesterolaemia: Quoad valetudinem long life treatment, European Journal of Preventive Cardiology, July 2019, SAGE Publications,
DOI: 10.1177/2047487319864191.
You can read the full text:
Contributors
The following have contributed to this page
